Printer Friendly

BioTime Receives FDA Approval to Market Hextend.

BERKELEY, Calif.--(BW HealthWire)--March 31, 1999--BioTime, Inc. (Nasdaq:BTIM) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market Hextend(R), the Company's physiologically balanced blood plasma volume expander, for the treatment of hypovolemia.

Hypovolemia is a condition often associated with blood loss during surgery or from injury. Hextend(R) maintains circulatory system fluid volume and oncotic pressure and keeps vital organs perfused during surgery. Hextend(R), approved for large-volume use in major surgery, is the only blood plasma volume expander that contains hetastarch, buffer, multiple electrolytes, and glucose. Hextend(R) is also completely sterile to avoid risk of infection.

"We are gratified that Hextend(R) has received approval," said Dr. Paul Segall, BioTime's chief executive officer. "We have been working closely with our North American marketing partner, Abbott Laboratories, and preparations for the market launch are moving forward."

BioTime, headquartered in Berkeley develops blood plasma volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, organ preservation solutions and technology for use in surgery, emergency trauma treatment, the preservation of organs awaiting transplant, and other applications.

The matters discussed in this press release include forward-looking statements which are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated. Such risks and uncertainties include but are not limited to BioTime's ability to obtain foreign regulatory approval to market Hextend; competition from products manufactured and sold or being developed by other companies; the price of and demand for Hextend; the Company's ability to negotiate favorable foreign licensing or other manufacturing and marketing agreements for its products; the availability of ingredients used in Hextend; and the availability of reimbursement for the cost of Hextend (and related treatment) from government health administration authorities, private health coverage insurers and other organizations. These and other risk factors are discussed in BioTime's Annual Report on Form 10-K filed with the Securities and Exchange Commission.
COPYRIGHT 1999 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Apr 1, 1999
Previous Article:Cover-All Technologies Inc. Reports Fourth Quarter Operating Results.
Next Article:Ventas, Inc. Filing of Annual Report On Form 10-K For Fiscal Year Ended December 31, 1998.

Related Articles
Turning the tables on drug companies; exposing deficiencies in FDA regulation.
FDA Completes Review of BioTime's New Drug Application for Hextend, BioTime Pleased With Quick Response.
Eleventh Circuit bars preemption in medical device case.
Hextend Sales Begin, BioTime Receives Milestone Payments.
BioTime to Begin Clinical Studies of PentaLyte, a New Blood Plasma Volume Expander.
BioTime Successfully Completes PentaLyte Phase I Clinical Trial; Hextend Used to Treat Hypovolemia in Cold Surgical Procedures.
Hextend's Potential to Help Alleviate Blood Shortages Puts BioTime in Individual Investor's ``Magic 25'' for 2001.
BioTime to Announce Growth in Sales of Hextend.
Sales of BioTime's Hextend Continue to Climb in 3rd Quarter 2001, Up 45% From Previous Quarter.
Judge rejects preemption in heart device case.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters